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Abstract
Background: Human immunodeficiency virus type 1 (HIV-1) infects macrophages effectively, despite relatively low levels of
cell surface-expressed CD4. Although HIV-1 infections are defined by viral tropisms according to chemokine receptor usage
(R5 and X4), variations in infection are common within both R5- and X4-tropic viruses, indicating additional factors may
contribute to viral tropism.
Methodology and Principal Findings: Using both solution and cell surface binding experiments, we showed that R5- and
X4-tropic HIV-1 gp120 proteins recognized a family of I-type lectin receptors, the Sialic acid-binding immunoglobulin-like
lectins (Siglec). The recognition was through envelope-associated sialic acids that promoted viral adhesion to macrophages.
The sialic acid-mediated viral-host interaction facilitated both R5-tropic pseudovirus and HIV-1BaL infection of macrophages.
The high affinity Siglec-1 contributed the most to HIV-1 infection and the variation in Siglec-1 expression on primary
macrophages from different donors was associated statistically with sialic acid-facilitated viral infection. Furthermore,
envelope-associated sialoglycan variations on various strains of R5-tropic viruses also affected infection.
Conclusions and Significance of the Findings: Our study showed that sialic acids on the viral envelope facilitated HIV-1
infection of macrophages through interacting with Siglec receptors, and the expression of Siglec-1 correlated with viral sialic
acid-mediated host attachment. This glycan-mediated viral adhesion underscores the importance of viral sialic acids in HIV
infection and pathogenesis, and suggests a novel class of antiviral compounds targeting Siglec receptors.
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Introduction
Human immunodeficiency virus type 1 (HIV-1) infection of
macrophages and T cells requires both CD4 and chemokine
receptors [1]. While binding to CD4 provides mainly viral
attachment to host cells, the interaction of the viral envelope
protein gp120 with chemokine receptors initiates conformational
changes leading to the fusion and entry of the virus [2]. Although
CD4
+ T cells are the major target of HIV, macrophages represent
a potentially long-lived viral reservoir that may help the virus resist
eradication [3,4]. Furthermore, infected macrophages appear to
contribute to dementia and neural dysfunction in infected
individuals [5]. However, unlike CD4
+ T cells, macrophages
express relatively low levels of CD4 thereby complicating efficient
viral entry [6]. Additional attachment factors, including carbohy-
drate receptors, have been proposed to facilitate infection of
macrophages [7].
On their surface, macrophages express a number of C-type
lectins, including the macrophage mannose receptor (MMR) and
DEC-205. Although both the MMR and DEC-205 can capture
HIV-1 through recognition of mannose-associated glycans on the
viral envelope protein, binding to these receptors results primarily
in non-productive infection or internalization of the virus for
antigen presentation [8,9,10,11]. In addition to the C-type lectins,
macrophages also express a number of Sialic acid-binding
immunoglobulin-like lectins (Siglec). In humans, the Siglec family
is comprised of a total of 14 different genes that specifically
recognize terminal sialic acids associated with both N- and O-
linked glycosylations. They are expressed mainly on lymphoid and
myeloid lineage cells where they promote cell-to-cell adhesion
through binding to cell surface-associated sialic acids [12]. Siglecs
are also known to recognize heavily glycosylated mucins and
mucin-like domains [13,14].
Like many enveloped retroviruses, the envelope protein of HIV-
1 is heavily glycosylated. The crystal structure of the viral envelope
protein revealed the molecular details of the CD4 binding site on
gp120 [15,16]. Mutations in gp120 that remove N-linked glycan
sites on both HIV and SIV have resulted in viruses that are more
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shielding against host immune detection [17,18,19]. However,
some of the mutants, especially those with multiple glycan
mutations, also displayed much lower viral infectivity and
syncytia-forming ability compared to the wild-type viruses,
indicating a potential involvement of these glycans in viral entry.
The best studied example involving sialic acid in viral entry is
the Orthomyxoviridae family of influenza viruses, which use
hemagglutinin as the attachment receptor to bind to cell surface
sialic acids [20,21]. HIV and many other enveloped viruses do not
encode hemagglutinin for sialic acid binding. Rather, these viruses
can have N-terminal sialic acid bound to envelope-associated
proteins, like gp120 on HIV-1. Interestingly, it has been shown
that removal of cell surface sialic acids via neuraminidase
treatment enhances HIV infection [22]. Recently, evidence
suggests that sialoadhesin (Siglec-1) on a transfected monocytic
cell line can interact with HIV-1 [23]. In addition, Siglec-1
expression is up-regulated on certain populations of monocytes
upon HIV-1 infection [24]. It is not clear, however, whether
Siglec-1 recognizes heavily glycosylated viral envelope proteins,
such as HIV-1 gp120, and if the increased expression of Siglec-1
would facilitate viral attachment and entry. Here, we systemati-
cally evaluated the interactions between Siglecs and gp120 in
solution, on receptor-transfected cells, and on primary monocyte-
derived macrophages (MDM), and examined the potential
importance of Siglec-gp120 interactions in HIV-1 infection.
Results
Recombinant Siglec receptors bound soluble gp120 from
both R5- and X4-tropic strains of HIV-1 in solution
gp120, a surface envelope protein on HIV-1, encodes over 20
N-linked glycosylation sites. Many of these sites are conserved
between CCR5- (R5) and CXCR4-tropic (X4) strains of the virus
[25,26]. Approximately half of these sites carry a complex type of
carbohydrate with terminal sialic acid modifications [25]. The
others are a mixture of high mannose or hybrid types of
carbohydrates. Interestingly, the glycans on the five gp120 variable
loops are almost exclusively of the complex type (Figure 1A).
When the glycans are displayed onto a model of a gp120 trimer
Figure 1. A structural model of gp120 and associated glycans. (A) Location of glycosylation sites on the IIIB strain of HIV-1 gp120 with
complex (y) and high mannose or hybrid (Q) types. (B) Distribution of glycans on HIV-1 gp120 and gp41 trimer (cyan) in complex with CD4 (red).
Coordinates for the gp120 trimer model with two-domain CD4 was kindly provided by P. Kwong [27]. The four-domain CD4 model (pdb code 1WIO)
is placed in the complex by superposition of the two N-terminal domains. The view is from host cell down to virus. The V1 and V2 loops are drawn in
the figure, as both loops are missing in the crystal structure of the gp120 and CD4 complex (pdb code 1GC1). Subunits are color-coded cyan for gp41
and gp120, red for CD4, magenta for complex-type carbohydrates, and green for high mannose and hybrid type-carbohydrates. The V3 loop region is
denoted by a red circle.
doi:10.1371/journal.pone.0024559.g001
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of the trimer, and are potentially available to bind sialic acid
receptors (Figure 1B). This raises an intriguing possibility that sialic
acids on gp120 may facilitate viral attachment and entry through
direct binding to Siglecs.
Since Siglec receptors are known to recognize sialic acids on
mucin-like glycoprotein, we used a surface plasmon resonance
(SPR) technique to investigate if gp120-associated sialic acids can
be recognized by Siglecs [28,29]. We performed direct binding
between various recombinant gp120 proteins and the five soluble
human Siglec receptors (Siglec-1, -3, -5, -7, and -9) expressed on
monocytes. When captured on an immobilized protein A
sensorchip, Siglec-1 and -9 Fc fusion receptors bound readily to
various gp120 envelope proteins with affinities varied between
0.01–1 mM (Figure 2A). Their gp120 binding affinities were
similar to their binding affinities to polyacrylamide-conjugated
sialoglycans (Table 1, Figure 2B), suggesting that the observed
Siglec-gp120 interactions were specific. Interestingly, both Siglec
receptors recognized multiple strains of gp120, albeit with different
affinities, from both R5- and X4-tropic viruses. For example,
Siglec-9 bound to the R5-tropic envelopes from 93UG037,
SIVsmm PBj1.9, and 92US715 isolates with affinities between
0.02 and 0.3 mM while it bound to the X4-tropic envelopes from
92UG21-9 and NL4-3 strains of HIV-1 with 0.05 and 0.12 mM
affinities, respectively.
Furthermore, as gp120 exists in a trimeric state on HIV-1, we
also examined the binding affinities of Siglec-1, -5, -7 and -9 to a
trimeric gp120 derived from the 93UG037 isolate, and observed a
three to five-fold increase in affinities compared to the monomeric
gp120 from the same strain, with the exception of Siglec-9, that
showed similar affinity with both the monomeric and trimeric
gp120 (Table 1). Compared to Siglec-1 and -9, Siglec-3, -5, and -7
proteins displayed low affinity binding to gp120 when the
receptors were captured at similar levels. However, the gp120
binding affinities for Siglec-3, -5, and -7 increased between 100- to
1000-fold when the receptors were immobilized at three to five-
fold higher surface densities (Table 1, Figure 2C), indicating an
avidity contribution to the Siglec-gp120 recognition. In contrast,
the affinity of Siglecs for polyacrylamide-conjugated a(2,3)-
sialyllactose, a(2,6)-sialyllactose, and a(2,8)-disialic acid was
consistently in the micromolar range, independent of receptor
immobilization density (Table 1). This profound avidity effect of
Siglecs binding to gp120, but not to PAA-conjugated carbohy-
drates, indicates that the level of Siglec expression on the surface of
a cell may affect sialic acid-mediated viral attachment.
To investigate whether Siglec-gp120 interactions were indeed
mediated by sialic acid, we examined the binding between
92US715 gp120 and Siglec-9 in the presence of a competitor,
a(2,6)-sialyllactose (69SL). The binding of Siglec-9 to both gp120
and a control sialic acid polymer, a(2,8)-disialic acid polyacryl-
amide conjugate, was inhibited by 16 mM a(2,6)-sialyllactose
(Figure 2D). Consistently, treating R5-tropic gp120 (92US715)
with peptidyl-N-glycanase-F to enzymatically remove N-linked
glycans also reduced gp120 binding to Siglec-9. Overall, the
solution binding results showed that Siglec receptors recognized
various recombinant gp120 proteins with Siglec-1 and -9
displaying higher binding affinities than Siglec-3, -5, and -7. The
Siglec binding affinities also varied among gp120 derived from
different HIV and SIV isolates.
Siglec-transfected CHO cells recognized recombinant
HIV-1 gp120
To examine if the binding between Siglec receptors and
gp120 observed in solution also occurred on the cell surface, we
established stable CHO cell transfectants expressing human
Siglec-1, -3, -5, -7 or -9 individually (Figure S1). Cell surface
binding between a biotin-labeled recombinant soluble gp120
from the 93MW959 isolate (R5-tropic subtype C) and two of
the Siglec-transfected cell lines (Siglec-1 and -3) was readily
observed by FACS analysis (Figure 3A). Furthermore, when
two CHO cell-transfectants with different Siglec-1 expression
levels were compared, the fluorescence intensity of cell surface-
bound gp120 correlated with the level of Siglec-1 expression
(Figure 3C), and the gp120 binding was inhibited by a Siglec-1
blocking antibody (Figure 3D). This indicates that the
recognition was indeed mediated by the transfected receptor.
To address if the Siglec binding site on gp120 overlaps with
that of CD4 binding, biotinylated gp120 was pre-incubated
with a recombinant soluble CD4 prior to binding to Siglec-1
transfected CHO cells (Figure 3D). The result showed that the
presence of CD4 did not affect the gp120 binding to Siglec-1,
suggesting that Siglec-1 binding site on gp120 is separate from
that of CD4. Neuraminidase (NA) treatment of Siglecs
expressed on the cell surface often enhances their trans-ligand
recognition, presumably due to the removal of cis-bound or
‘‘masking’’ sialic acids [30]. Siglec-1, which contains 17
extracellular domains, is the largest Siglec receptor and is
likely least masked with sialic acids. Overall, Siglec-1, -3, -5 and
-9 transfected CHO cells exhibited enhanced binding to
recombinant 93MW959 gp120 when treated with neuramini-
dase (Figure 3B). In addition, when the recombinant gp120 was
treated with neuraminidase to remove the envelope-associated
sialic acids, binding to Siglec-1 and Siglec-9 transfectants was
reduced significantly compared to untreated gp120 (Figure 3E).
A similar reduction in binding was also observed when the
soluble gp120 was treated by mild periodate oxidation, which
truncates the glycerol side chain of sialic acids and leads to the
loss of Siglec recognition [31,32] (Figure 3E). To further
demonstrate that Siglec binding to HIV-1 depends on gp120-
associated sialic acids, CHO cell binding experiments were
carried out in the presence of either sialyllactose, a known
ligand of Siglec receptors [28], or lactose. Our results showed
that sialyllactose inhibited the 93MW959 gp120 attachment to
the Siglec-1 or -9 transfected cells while lactose, an analogue
lacking sialic acid, did not affect the gp120 binding (Figure 3F).
Siglec receptors on macrophages recognized soluble
gp120
Freshly isolated human monocytes were differentiated into
macrophages using M-CSF and GM-CSF. The differentiated
macrophages expressed a significant amount of Siglec-3 and -9,
low levels of Siglec-1 and very little Siglec-5 and -7, compared with
monocytes which express higher levels of Siglec 5 (Figures 4A &
B). Using biotinylated gp120 from either an R5- (93MW959) or an
X4-tropic (92UG21-9) isolate of HIV-1, we examined gp120
binding to monocyte-derived macrophages (MDM) both in the
presence and absence of a CD4-blocking antibody. The results
showed that gp120 binding was enhanced significantly on cells
treated with neuraminidase (Figure 4C), consistent with the
enhanced adhesion by Siglec receptors observed upon neuramin-
idase treatment in the transfected cells. Alternatively, when the
soluble R5- or X4-tropic gp120 was treated with neuraminidase or
sodium periodate, its binding to MDM was significantly reduced
(Figures 4D & E). These results showed sialic acid-mediated
binding of HIV-1 envelope protein to macrophages and suggest a
potential contribution of viral sialic acid in HIV-1 attachment to
the cell surface.
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24559Figure 2. SPR experiments between gp120 and Siglecs. (A) Binding of recombinant gp120 from 92US715 (0.65 mM), 92UG21-9 (0.49 mM), and
93UG037 (0.2 mM) HIV-1 isolates onto protein A-captured recombinant Siglec-1, -5, -7, and -9 Fc fusion proteins. The sensorgrams in each panel
represent individual Siglecs captured in the order of decreasing surface densities between black, grey and dashed curves. Flow cell 1 has immobilized
protein A but no captured receptor (blank). The binding curves of gp120 to captured Siglec-3 are shown in Figure S2. (B) Binding of 10 mM a(2,8)-
sialyllactose-PAA (89SA-PAA) onto protein A-captured recombinant Siglec-1 and -9 Fc fusion proteins in similar settings as (A). (C) Binding of serial
dilutions of 92US715 gp120 between 0.43–0.054 mMo r8 9SA-PAA between 0.062–20 mM onto immobilized Siglec-5 and -7 under high immobilization
density. (D) Binding of 92US715 gp120 and 89SA-PAA to protein A-captured Siglec-9 in the presence of a(2,6)-sialyllactose (69-SL), and the effect of
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HIV-1 virus infection of macrophages
While recombinant HIV-1 gp120 from various strains bound to
Siglec receptors in solution, on transfected cells, and on
macrophages, it was not clear if the sialic acid-mediated gp120
binding would promote viral attachment and entry. To address
this, we employed a luciferase-based single round infection assay
using HIV-1 luciferase virus pseudotyped with envelopes derived
from various HIV isolates or vesicular stomatitis virus (VSV) to
infect MDM. Consistent with preferred tropism profiles and
similar to previous observations [33], the infection of MDM by the
R5-tropic JRFL pseudovirus routinely yielded 5–10 times higher
luciferase activities (ALU) than that by a dose equivalent X4-tropic
SF33 pseudovirus (Figure 5A). To examine the contribution of
viral sialic acid to HIV-1 infection, we carried out the pseudovirus
infection of MDM in the presence of sialyllactose or lactose, fetuin
or its sialic acid-deprived form, asialofetuin. The addition of
sialyllactose resulted in a dose-dependent inhibition of JRFL but
not VSV pseudovirus infection (Figure 5A). Only the highest dose
of sialyllactose inhibited the SF33-pseudotyped virus infection.
Similar to the observed binding between a recombinant gp120 and
Siglec receptors on transfected CHO cells, the pseudovirus
infection was preferentially inhibited by 50 mg/ml sialyllactose
not lactose and by 1 mg/ml fetuin not asialofetuin (Figure 5B &
C). The failure of lactose and asialofetuin to inhibit the viral
infection at equal concentrations compared to their sialo-analog
demonstrated the importance of sialic acid in the infection.
Furthermore, the JRFL luciferase virus infection of MDM was
partially inhibited by soluble recombinant Siglec-1,-3, -7, and -9
proteins (Figure 5D, Figure S3). The extent of inhibition by the
individual Siglec proteins correlated with their binding affinities to
sialic acid and gp120 (Table 1). Namely, the high affinity soluble
Siglec-1 and -9 inhibited more than the low affinity Siglec-3. The
broad involvement of viral sialic acids in HIV-1 infection is evident
when MDM were infected with sodium periodate-treated
pseudoviruses from multiple strains of HIV-1. Disrupting sialic
acid with sodium periodate reduced the R5-pseudoviruses
infection by 20–60% (Figure 5E). Since periodate-treated gp120
exhibited a reduced binding to MDM, the observed decrease in
infection by periodate-treated virus is likely a result of reduced host
attachment mediated by viral sialic acid.
Siglec receptors contributed R5-pseudotyped HIV-1 virus
infection of macrophages
The involvement of carbohydrate recognition in HIV-1
infection has been controversial largely due to the use of cell lines
in early research discoveries [34,35]. This is also supported by the
known antiviral effects of many carbohydrate binding agents
(CBA), such as bacterial cyanovirin-N (CVN) and some plant
lectins [36]. Consistent with previous publications, our infection
experiment with JRFL pseudovirus was potently inhibited by
CVN; VSV infection of MDM was not affected (Figure 6A). While
CVN binding likely blocks viral access to both I-type and C-type
lectin receptors on macrophages, we evaluated the potential
deglycosylation of 92US715 gp120 on the binding of protein A-captured Siglec-9. All sensorgrams are shown in response units (vertical axis) versus
sample injection time (horizontal axis) in seconds. Dissociation constants are listed in Table 1.
doi:10.1371/journal.pone.0024559.g002
Table 1. Dissociation constants (KD) for gp120 binding to Siglec Receptors.
KD (mM) for HIV-1 strains
R5-Tropic X4-Tropic PAA
4
Isolates UG037
1 PBJ
1 US715
1 Trimer
2 UG21
1 NL4-3
1
39SL 69SL 89SA
Clades A SIV B A A B
Siglecs
Moderate Immobilization Density (2000–7000 RU)
Siglec-1 6.3 0.12 0.13 0.9 0.08 0.033 0.5 2.0 2.3
Siglec-3 ND
3 54.5 57.8 ND 3.8 ND 4.5 7.0 5.0
Siglec-5 20.3 50.5 9.4 5.1 47.1 ND 1.6 0.5 1.8
Siglec-7 9.9 35.4 53.4 2.7 49.2 ND 1.5 1.0 0.9
Siglec-9 0.10 0.27 0.023 0.08 0.05 0.012 0.5 0.3 2.9
High Immobilization Density (12000–20000 RU)
UG037
1 PBJ
1 US715
1 MW959
1 UG21
1 NL4-3
1 39SL 69SL 89SA
Siglec-3 0.051 0.18 0.008 0.012 0.08 0.009 13 2.1 4.8
Siglec-5 0.054 0.014 0.02 0.015 0.05 0.008 13 11.1 2.2
Siglec-7 0.094 0.019 0.04 0.02 0.05 0.013 1.7 2.5 1.9
1The strain abbreviations with Genbank accession numbers in parenthesis are: UG037 for 93UG037 (U51190), PBJ for SIVsmm PBj1.9 (M31325), US715 for 92US715
(U04919), UG21 for 92UG21-9 (U08804), NL4-3 (M38432), MW959 for 93MW959 (Clade C, U08453).
2The trimeric gp120 is from the 93UG037 strain. The recombinant protein was expressed in CHO cells fused with a trimerization domain from T4 bacteriophage fibritin
[51,52].
3ND: Not Done.
4The symbols for polyacrylamide (PAA)-conjugated model carbohydrates are 39SL, 69SL, and 89SA for a(2,3)-sialyllactose-PAA, a(2,6)-sialyllactose-PAA, and
Neu5Aca(a2,8)-Neu5Aca(a2,8)Neu5Aca-sp-PAA, respectively.
doi:10.1371/journal.pone.0024559.t001
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PLoS ONE | www.plosone.org 5 September 2011 | Volume 6 | Issue 9 | e24559Figure 3. Recombinant biotin-labeled gp120 from the 93MW959 isolate (R5-tropic subtype C) binding to Siglec-transfected CHO
cells. (A) Untransfected (open histogram) or Siglec-transfected CHO cells (grey histogram) were incubated with gp120 after being blocked with BSA
and murine IgG, and then stained with PE-conjugated streptavidin. (B) The panels are similar to (A) except the cells were pretreated with
neuraminidase (NA). (C) The Siglec-1 expression levels detected by an anti-Siglec-1 antibody (top panel) from clones 118 (open histogram) and 78
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mannan, and EDTA. Compared to the sialylated compounds,
compounds specific for C-type lectin receptors exhibited less
inhibition to JRFL-pseudovirus infection even though EDTA
potently inhibited VSV pseudovirus infection (Figures 5B & 6A).
This suggests a unique role for Siglecs recognition of viral
sialylated glycans in HIV-1 attachment and entry.
To further investigate the contribution of individual Siglec
receptors to viral attachment, we carried out pseudovirus
infections in the presence of blocking antibodies against the major
macrophage-expressed Siglecs, Siglec-1, -3 and -9. Blocking
Siglec-1 or -3 reduced JRFL infection of MDM to 20% and
70%, respectively, compared to the PBS control (Figure 6B).
Blocking Siglec-9, however, did not affect the infection, even at an
antibody concentration of 100 mg/ml. These data demonstrate a
preferential involvement of Siglec-1 in HIV-1 infection of MDM.
This is also consistent with the high affinity binding of Siglec-1 to
gp120 relative to other Siglecs (Table 1). The striking difference
between blocking Siglec-1 and -9 is interesting even though both
recombinant proteins bind gp120 well in solution. Their
preferential usage by HIV-1 may be related to their differential
masking by cell surface cis-sialic acid. This is consistent with our
gp120 binding experiment, which shows that the binding of gp120
to Siglec-9 transfected CHO cells requires neuraminidase
treatment, unlike Siglec-1 (Figure 3B). Siglec-1 has 17 extracellular
domains and is likely less masked than the three-domain Siglec-9.
To further address the potential contribution of masked Siglec
receptors on macrophages, we treated MDM with neuraminidase
prior to HIV-1 infection. Indeed, treating MDM with neuramin-
idase significantly increased luciferase virus infection for multiple
strains of pseudotyped HIV-1 (Figure S4), suggesting a potential
contribution by masked Siglecs to the viral infection under certain
conditions.
Viral sialic acids facilitate R5-tropic HIV-1BaL infection of
macrophages
To explore if viral sialic acids also facilitate productive HIV-1
infection, we examined the effect of sialyllactose on MDM
infection using a replication competent R5-tropic HIV-1BaL virus
that was propagated in primary human macrophages. Virus
production in human macrophages ensures a physiologically
relevant glycosylation compared to that of the 293T cell-produced
pseudoviruses. The infections were performed in the presence of
sialyllactose, lactose, PBS, or a known entry inhibitor, T20, and
evaluated based on viral p24 antigen level in the supernatant
collected over a two-week period. Similar to the luciferase virus
infections, HIV-1BaL infection of MDM was reduced significantly
by sialyllactose compared to PBS or lactose at all time points
(Figures 6C–D, Figure S5 & Figure S6).
Strain variation of R5-tropic viruses affected sialic acid-
mediated viral attachment
Compared to the relatively conserved CD4 binding site on
gp120, the positions of viral glycan sites are less conserved,
implying a potential variation in sialic acid-facilitated viral entry.
The heterogeneity of glycosylation modification could further
affect the sialic acid content on viral envelopes. The variation in
sialic acid-dependent infection is evident when comparing the
infection of macrophages by four different strains of R5-tropic
HIV-1 (JRFL, DH125, AD8 and HW1) pseudoviruses treated with
sodium periodate (Figure 5E). The mild periodate treatment of
viruses resulted in a 40–60% reduction in infection by DH125 and
AD8, but only a 20% reduction by JRFL and HW1 isolates. In
addition, treatment of macrophages with neuraminidase resulted
in diverse enhancement of infection among the four strains of
viruses (Figure S4), suggesting a strain variation in sialic acid-
mediated viral attachment.
Variation in Siglec expression associated with sialic acid-
dependent viral attachment
In addition to viral strain-associated variation in sialic acid
content, variations in host Siglec receptor expression may also
affect sialic acid-facilitated viral entry. To address this, we carried
out pseudovirus infections (JRFL and VSV) of MDM from five
individuals (donors 1–5) in the presence of sialyllactose (Figure 7A).
The result showed that the sialyllactose-mediated inhibition of
JRFL pseudovirus infections varied between 30%–80% among the
five donors. To specifically examine if Siglec-1 contributed to
donor variation in sialic-acid dependent entry, similar JRFL
pseudovirus infections were carried out in the presence of the anti-
Siglec-1 antibody instead of sialyllactose (Figure 7B). The result
showed that while the antibody nearly completely blocked the
infection of MDM from donor 13, with less than 5% residual
infection, the inhibitory effect was more marginal in two of the
four donors. Thus, Siglec-1 can play a critical role in HIV-1
infection and may contribute to the observed host variation in
sialic acid-dependent viral attachment.
To further examine variations in infection contributed by
different hosts, we carried out productive infections of MDM from
seven donors (donors 6–12) with HIV-1BaL in the presence of
sialyllactose (Figure 7C). Similar to pseudovirus infections,
sialyllactose inhibition of HIV-1BaL varied between 10%–80%
relative to the control. To delineate the factors important for sialic
acid-mediated HIV-1BaL infections, we measured the expression
levels of multiple surface markers from these donors and analyzed
the statistical association between their expression and the
sialyllactose-mediated inhibition of the infections using Spearman
correlations (Figures 7D–I). The expression markers, which varied
among the seven donors, included the known HIV-1 entry
receptors, CD4 and CCR5; the major macrophage sialic acid
receptors, Siglec-1, Siglec-3 and Siglec-9; and a lineage-specific
marker for macrophages, CD14. If sialyllactose has a specific
receptor target, its inhibition effect would be expected to correlate
with the expression of the receptor. Conversely, the expression of
receptors not associated with sialyllactose would not be expected to
correlate with its inhibition outcome. Indeed, the expression of
CD14 was not correlated with sialyllactose-mediated inhibition to
HIV-1BaL infection with a p-value of 0.56 in a Spearman two-
tailed correlation analysis with 95% confidence interval (Figure 7I).
Interestingly, the expression of known HIV-1 entry receptors,
CD4 and CCR5, also failed to correlate with the inhibition
outcome (p-values=0.78 and 0.66, respectively), suggesting that
the sialyllactose-mediated inhibition is not related to the CD4 and
(grey histogram) of transfected CHO cells correlated with their binding to gp120 (bottom panel). (D) Binding of gp120 to Siglec-1 transfected CHO
cells in the presence (grey histogram) or absence (open histogram) of 50 mg/mL human Siglec-1 blocking antibody (top) or pre-incubated with (grey
histogram) or without (open histogram) 50 mg/mL recombinant soluble CD4 (bottom). Dotted lines correspond to staining with PE-conjugated
streptavidin only. (E) Binding of gp120, untreated (open), NA or sodium periodate (NaIO4) treated (grey), to Siglec-1, or Siglec-9-transfected CHO cells.
Siglec-9-transfected cells were pretreated with NA. (F) Binding of gp120 to Siglec-1 or Siglec-9 transfected CHO cells in the presence of titrating a2,3-/
a2,6-sialyllactose (grey) or lactose (white).
doi:10.1371/journal.pone.0024559.g003
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direct correlation (p-value=0.012) with sialyllactose-mediated
inhibition of infection (Figure 7D). Higher Siglec-1 expression
was associated with increased sialic acid-dependent entry and
hence became more sensitive to sialyllactose inhibition. Although
the expression correlations of Siglec-3 and -9 failed to reach
statistical significance (Figures 7E–F), Siglec-3 expressions appear
to generally correlate with the sialyllactose inhibition with the
exception of one donor, suggesting a potential contribution of
Siglec-3 in certain situations of HIV-1 infection. These results are
also consistent with the antibody blocking of JRFL pseudovirus
infections showing that Siglec-1 was the major facilitating receptor
with possible minor contributions from Siglec-3 to HIV-1 infection
(Figure 6B).
Discussion
Macrophages represent an important target and potentially
long-lived reservoir for R5-tropic HIV-1 [3,4]. Unlike CD4
+ T
cells, which express abundant CD4, macrophages express
Figure 4. Siglec expression and recombinant gp120 binding to human monocytes or MDM. (A) The expression of Siglecs (grey) on CD14
+
monocytes. (B) The expression of Siglecs (grey) on CD14
+ MDM. The controls were stained with PE-conjugated isotype-matched IgGs. All samples
were blocked with mouse IgG prior staining. (C) Binding of biotinylated gp120 from 93MW959 (top) or 92UG21-9 (bottom) isolates to NA-treated
(grey) or untreated (open) MDM in the presence (left) or absence (right) of a CD4-blocking antibody (OKT4). (D, E) Binding of biotinylated 93MW959
(top) or 92UG21-9 (bottom) recombinant gp120, untreated (open histogram) or treated (grey histogram) with NA (D) or NaIO4 (E) to NA treated MDM
in the presence of a CD4-blocking antibody (OKT4).
doi:10.1371/journal.pone.0024559.g004
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investigated whether HIV-1 utilizes additional attachment
receptors to facilitate entry into macrophages. We showed that
glycans present on HIV-1 gp120 interact with Siglecs, a family
of I-type lectin receptors. Both in solution and on transfected
cells, recombinant gp120 proteins recognized Siglecs through
gp120-associated sialoglycans independent of CD4 binding. The
binding affinities of gp120 for Siglecs varied substantially
depending on the isoforms and densities of Siglecs as well as
strains of HIV-1. Importantly, the gp120 bindings to Siglec
receptors were inhibited by sialyllactose but not lactose. Also,
disrupting the sialic acid structure with sodium periodate
significantly reduced the bindings. Additional binding experi-
ments using neuraminidase to remove cell surface-associated
sialic acid on Siglec-transfected CHO cells showed receptor
variations in a phenomenon known as ‘‘masking’’. Part of the
neuraminidase effect is to unmask Siglec receptors on the cell
surface thus increasing their binding to viral sialic acids. Siglec-1
Figure 5. Single-round infection assays using R5- and X4-tropic HIV pseudoviruses. Except for panel A, which is shown in Arbitrary Light
Units (ALU), the levels of viral entry (grey bars) are shown as percentage compared to their respective controls (open bars). (A) R5 and X4-tropic HIV
and VSV entry into MDM in the presence of (from left to right) 0, 0.1, 1, 10, or 50 mg/mL sialyllactose (SL). (B) Entry of JRFL and VSV into MDM in the
presence of 50 mg/mL SL or lactose, 1 mM EDTA, or PBS. (C) R5- and X4-tropic HIV-1 and VSV entry into MDM treated with 50 mg/mL SL, 1 mg/mL
asialofetuin, 1 mg/mL fetuin, or PBS. (D) Entry of JRFL and VSV into MDM in the presence of 100 mg/mL recombinant Siglec-1, Siglec-3, Siglec-9,
50 mg/mL SL, or PBS. (E) Infection of MDM using R5-(left side) and X4-(right side) tropic HIV pseudoviruses treated with 1 mM NaIO4 (grey) or glycerol
(white). Results are representative of one out of three experiments.
doi:10.1371/journal.pone.0024559.g005
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t r e a t m e n t( F i g u r e3 ) ,s u g g e s t i n gt h a tm o s to fS i g l e c - 1e x i s t si na n
unmasked state, likely due to its large size with 17 predicted
immunoglobulin domains [29]. In contrast, Siglec-9, although a
high affinity receptor for sialic acid, displayed significant
adhesion only after neuraminidase treatment, suggesting most
o ft h er e c e p t o r sa r em a s k e do nc e l ls u r f a c e .
Consistent with the binding results, HIV-1 R5-pseudovirus
infections of MDM were preferentially inhibited by sialo- but not
their asialo-compounds and by sodium periodate treatment of the
viruses. However, the effects of the sialyllated compounds in X4
infections were less conclusive as X4-viruses infect macrophages at
a very low level due to the preferential usage of CXCR4. The
results of Siglec blocking antibodies on R5-pseudovirus infection
further defined the contribution of individual Siglec receptors in
HIV-1 infection of macrophages. The preferential involvement of
Siglec-1 and, to a lesser extent, Siglec-3 was observed in JRFL
pseudovirus infections blocked by Siglec antibodies, as well as
sialyllactose-inhibited HIV-1BaL infections. These results are also
consistent with gp120 binding experiments using Siglec-transfect-
ed CHO cells. Thus, the contribution of Siglec-1 in HIV-1
infection reflects its high binding affinity to sialic acid and
favorable availability for viral attachment.
While the exact distributions of viral sialic acids on HIV-1
isolates remain unknown, their predicted N-glycan sites vary
significantly both in positions and numbers. In contrast to
conserved CD4 binding site on gp120 [16], half of the
glycosylation sites in gp120 variable loop regions are not conserved
among different strains (Figure S7). The variations in viral
envelope sialyloglycan distribution may very well result in
variations in Siglec-dependent viral attachment, consistent with
the observed variations in sialic acid-dependent infections among
JRFL, DH125, AD8 and HW1 strains of HIV-1. In addition, host
factors could influence HIV-1 attachment. Interestingly, the
expression of Siglec-1 is up-regulated by inflammation and
infection, including HIV-1 infection [24,37]. This raises the
possibility that increased Siglec-1 expression on macrophages at
inflammatory sites may further enhance HIV replication and thus
contribute to viral dissemination. This is also consistent with a
recent finding of an association between immune activation and
progressive SIV infection in pigtail macaques [38]. Thus, viral
envelope glycan heterogeneities together with host Siglec expres-
sions could lead to a wide range of sialic acid-dependent host
susceptibilities to HIV infection.
In conclusion, we suggest that HIV-1 viruses utilize their
sialoglycans on the envelope protein to facilitate viral attachment
Figure 6. Effect of Siglec-specific compounds and blocking antibodies on pseudovirus and HIV-1BaL infections of MDM. (A) Entry of
JRFL and VSV into MDM in the presence of 500 ng/mL CVN, 100 mg/mL recombinant Siglec-9, 50 mg/mL mannose, 1 mg/mL mannan, 1 mM EDTA,
or PBS. (B) Infection of MDM with JRFL and VSV pseudoviruses in the presence of 20 mg/mL Siglec-1 and -3, 100 mg/mL of Siglec-9 blocking
antibodies, or 100 mg/mL control IgG (from mouse or sheep, open bars). (C & D) Infections of MDM with HIV-1BaL (125 TCID50/10
6 cells) were
measured in p24 (ng/mL) at various days post-infection (DPI) in the presence of 50 mg/mL SL (black circles), 100 mg/mL T20 (black triangles), or PBS
(open squares). Graphs A & B represent two infection experiments with different donor cells.
doi:10.1371/journal.pone.0024559.g006
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Siglec-1, and thus enhancing their binding to CD4 for productive
entry (Figure 8). While viral glycans are known to shield HIV and
SIV from host immune detection as some glycan deletion
mutations have resulted in increased sensitivities to neutralizing
antibodies [17,18], our study suggests that HIV-1 viral glycans
function not only as a shield to evade host detection but also as a
sword to facilitate host entry. This glycan-mediated viral adhesion
to host cells resembles physiological cell-cell adhesions between cell
surface sialoglycans and the same lectins. Although the number
and locations of gp120 sialoglycans important for Siglec
recognition remains to be determined, it is tempting to speculate
that some of the known entry-deficient glycan mutations in the V1
and V2 loops affect Siglec binding during viral entry. The
inhibition of viral-Siglec interactions exhibited by sialic acid-rich
compounds shown here suggests a novel class of antiviral
compounds based on sialic acid homologs.
Materials and Methods
Reagents
Unless otherwise specified, all reagents and chemicals were
purchased from Sigma-Aldrich Co. (St. Louis, MO). Recombinant
human Siglec-1-Fc was prepared from transiently-transfected
COS cells using a plasmid encoding the four N-terminal Ig
domains of hSiglec-1 fused to the Fc regions of human IgG1 [39].
Blocking antibodies against Siglec-1 and Siglec-9 (sheep polyclon-
al) were prepared by Rita Sharma in the Crocker laboratory;
mouse monoclonal anti-human Siglec-3 (clone 6C5/2) was
obtained from Abcam (Cambridge, MA). Other recombinant
Siglec-Fc, Siglec-1 (non-Fc fusion), and CD4 proteins were
purchased from R&D Systems, Inc. (Minneapolis, MN). The
mouse anti-human CD4 monoclonal antibody (Leu3A), antibodies
against CD14, CXCR4, CCR5, and their isotype controls (IgG1
and IgG2A) were obtained from BD Biosciences (San Jose, CA).
PE-conjugated mouse anti-human Siglec-1 used for the FACS
analysis of MDM was purchased from Santa Cruz Biotechnology
(Santa Cruz, CA) or Biolegend (San Diego, CA). FACS antibodies
against other Siglecs were obtained from R&D Systems, Inc. or
BD Biosciences. Macrophage colony-stimulating factor (M-CSF)
and granulocyte-macrophage colony stimulating factor (GM-CSF)
were purchased from Peprotech Inc. (Rocky Hill, NJ). Polyacryl-
amide (PAA)-conjugated model carbohydrates were obtained from
Glycotech, Inc. (Rockville, MD). The recombinant gp120 proteins
were expressed in CHO cells in monomeric forms as previously
described [40,41]. Recombinant cyanovirin-N was prepared from
a bacterial expression plasmid provided by Dr. Mori, as described
[42]. Neuraminidase from Arthrobacter ureafaciens was purchased
from Roche Diagnostics (Indianapolis, IN). Peptide N-glycanase
was obtained from Boehringer Mannheim (Amsterdam, Nether-
lands). CellTiter-Glo Luminescent Cell Viability Assay and
Luciferase Assay System were purchased from Promega Corpo-
ration (Madison, WI). HIV-1 p24 ELISA kit was obtained from
PerkinElmer Life Sciences, Inc. (Waltham, MA). For FACS
analysis, recombinant gp120 proteins were labeled with biotin
using a biotinylation kit from Pierce Biotechnology (Rockford, IL).
RPMI, penicillin/streptomycin, fetal bovine serum, HEPES, and
Versene for MDM experiments were purchased from Invitrogen
Corporation (Carlsbad, CA).
Surface plasmon resonance (SPR) measurements
Solution binding studies were performed using a BIAcore 3000
instrument (GE Healthcare). Recombinant Siglec-Fc proteins were
immobilized onto carboxymethylated dextran (CM5) surface-
based sensor chips by either a capture with immobilized protein A
or primary amine-mediated direct surface cross-link. The
functional integrity of immobilized Siglec receptors was assessed
by their binding to specific antibodies as well as to polyacrylamide
(PAA) conjugated model carbohydrates, a(2,3)-sialyllactose (39SL-
PAA), a(2,6)-sialyllactose (69SL-PAA), and a(2,8)-disialic acid
(89SA-PAA). Recombinant gp120 proteins with varying concen-
trations between 10–500 nM, in either PBS or HBS-P buffer, were
injected over immobilized receptors at a flow rate of 20 mL/min.
The dissociation constants were determined from kinetic curve
fitting using the BIAevaluation software (GE Healthcare). For
competitive binding experiments, various gp120 samples were
injected onto captured Siglec sensorchips in the presence of either
1.6 or 16 mM concentrations of a(2,6)-sialyllactose.
Figure 7. Host variation in pseudovirus and HIV-1BaL infections of MDM. (A) Infections of MDM from five separate donors with JRFL, SF33 or
VSV pseudoviruses in the presence of 50 mg/mL SL or PBS. Levels of viral entry (grey bars) are shown as percentage compared to PBS control (shown
as a dotted line at 100% level). (B) Infections of MDM from four separate donors with JRFL pseudovirus in the presence of 20–100 mg/mL anti-Siglec-1
antibody (grey bars) or control sheep IgG (white bar). 100 ug/mL a-Siglec-1 was used in experiments with donors 13, 14, and 15; 20 ug/mL a-Siglec-1
was used with donor 16. Results are representative of one out of three experiments. (C) Relative infection levels from seven separate donors
compared to their PBS controls on days 12 or 14 post-infection with the HIV-1BaL in the presence of 50 mg/mL SL (patterned bars) or PBS (dotted line
at 100% level). (D–I) HIV-1BaL relative infection levels plotted against host expression of Siglec-1 (D), Siglec-3 (E), Siglec-9 (F), CCR5 (G), CD4 (H), and
CD14 (I). The error bars on donors 6, 9, and 11 are less than 1% and do not appear in the figure. p-values were generated using Spearman correlation.
doi:10.1371/journal.pone.0024559.g007
Figure 8. A model displaying the involvement of Siglec
receptors in HIV-1 infection of macrophages.
doi:10.1371/journal.pone.0024559.g008
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CHO-lec3.2.8.1 cells (kindly provided by Dr. Pamela Stanley)
[43], were cultured in DMEM/F12 medium supplemented with
5% FBS. pcDNA3.1 vectors containing coding regions for human
Siglec-1, -3, -5, -7 and -9, respectively, were transfected into the
CHO cells using Lipofectamine 2000 based protocol (Invitrogen
Corporation). G418-resistant colonies were cloned, expanded, and
screened for cell-surface Siglec expression based on FACS analysis
using their respective antibodies. The functionality of the stable
Siglec-transfected cells were confirmed by their preferential
binding to sheep red blood cells compared to untransfected
CHO cells.
Differentiation of monocyte-derived macrophages
(MDM)
Elutriated human monocytes were obtained from randomly
selected non-identified healthy donors from the Department of
Transfusion Medicine, National Institutes of Health. The
monocytes were plated at 1610
7 in 10 cm dishes in 10 mL
RPMI without serum. After attachment at 37uC for one hour,
differentiation was initiated in RPMI containing 10% FBS, 1%
penicillin/streptomycin with 1 ng/mL M-CSF and GM-CSF
[44]. Culture media was replaced on days 4 or 5 and on the day
prior to infection (usually day 7). Differentiated MDM were
detached from the plates using Versene and cell scrapers, and
then washed twice with RPMI. Total cell counts and viability
determinations were assessed with the Guava Personal Cell
Analysis System (Guava Technologies); all assays were performed
with a cellular viability greater than 70%. The differentiated
MDM consistently displayed the surface expression of CD33
high,
CD14
+,C D 4
+, CCR5
+, and CXCR4
low by FACS analysis.
CCR5 expression on MDM was increased in the presence of
GM-CSF [45]. Siglec receptor expression was evaluated on
monocytes and MDM using PE-conjugated mouse anti-human
Siglec-1, -3, -5, -7, and -9 with PE-conjugated mouse IgG1 or
IgG2A as their isotype controls. All samples were blocked with
murine IgG prior to triple-staining with FITC-conjugated mouse
anti-human CD14 and APC-conjugated mouse anti-human
CD4.
Cell-surface binding analysis
All incubations were carried out on ice. The staining and wash
buffer was PBS containing 0.25% BSA, 1 mM EDTA and 0.1%
NaN3. Analyses were performed using a Becton-Dickinson FACS
Calibur flow cytometer (BD Biosciences). CHO wild-type cells,
Siglec-expressing CHO cells, and Versene-lifted MDMs were
untreated or treated with 0.4 U/mL of neuraminidase for 2 hours
at 37uC. After washing, CHO cells were blocked with 0.2 mg/mL
murine IgG; MDMs were blocked with 0.2 mg/mL human IgG in
the presence or absence of a CD4 blocking antibody (5 mg/mL).
Cells were then incubated for 30 minutes with biotin-labeled
gp120 followed by PE-conjugated streptavidin. For blocking tests,
cells were incubated with blocking reagents prior to the incubation
with gp120. To remove gp120-associated sialic acids, proteins
were treated with neuraminidase (0.4 U/mL, 2 hours at 37uC) or
periodate (1 mM, in dark at room temperature for 10 minutes and
terminated by glycerol) before incubation with cells.
Preparation of the pseudotyped HIV viruses
Single-round replication-competent luciferase viruses pseu-
dotyped with various HIV-1 and VSV envelopes were
generated. The HIV viral vector, pNL4-3.Luc.R-E-, which
contains a firefly luciferase gene inserted into the NL4-3 HIV
nef gene and frameshift mutations to render it as env
2,w a s
used to generate all pseudotyped viruses [46,47]. In brief, the
expression vectors for pNL4-3.Luc.R-E-, the amphotropic
envelope pHEF-VSVG, and the R5-tropic HIV JRFL envelope
were obtained through the NIH AIDS Research and Reference
Reagent Program. Expression vectors for other HIV-1 enve-
lopes, including the dual-tropic isolate DH125 and R5-tropic
isolate AD8, were obtained from M. Martin [48]. The R5-
tropic isolate HW1 and its related X4-tropic HW2 counterpart
were generated on the backbone of the X4-tropic SF33
expression vector, pTEJ8-SD-envSF33, as previously described
[33]. Recombinant HIV luciferase viruses were generated by
co-transfecting 293T cells with 5 mg of the NL4-3 backbone
and either 5 mg of the HIV envelopes or 1.5 mgo ft h eV S V
envelope, as previously described [33]. Virus collected in the
culture supernatant were quantified by HIV p24 ELISA and
adjusted to 1 mg/mL p24.
Single-round infection assay
MDM were resuspended at 2610
6/mL in culture media.
Aliquots of 200 mL( 4 610
5 cells) were transferred to 15 mL tubes
for incubation with sialyllactose (Sigma-Aldrich A0828), lactose,
cyanovirin-N, fetuin, asialofetuin, and EDTA, individually, at
room temperature for 15 minutes prior to the addition of virus.
Luciferase viruses pseudotyped with envelopes from R5- and X4-
tropic HIV-1 and VSV were added to the cells at a
concentration of 100 ng/mL HIV p24. Where appropriate,
viruses were individually incubated with recombinant Siglec
proteins, mild periodate oxidation, or glycerol, prior to
incubation with cells. After incubating cells and virus at 37uC
for three hours with occasional agitation, the cells were washed
twice with a wash buffer (PBS, 2% FBS, 1% penicillin/
streptomycin, 12 mM HEPES), and once with culture media.
The infected MDM were then distributed into 96-well plates in
triplicate, incubated for 72 hours, lysed, and assayed for
luciferase activity according to manufacturer’s recommendations
(Promega). The concentrations of compounds used in pseudo-
virus infections are as follows: 1–50 mg/mL of sialyllactose,
50 ng/mL recombinant cyanovirin-N, 1 mg/mL fetuin, 1 mg/
mL asialofetuin, 100 mg/mL of the recombinant Siglec-3, -7 and
-9, 1 mM NaIO4,1 0m Mg l y c e r o la n d2m ME D T A .F o rt h e
infections, MDM were not treated with neuraminidase unless
specified. In that case, 0.5 U/mL of the enzyme was incubated
with MDM for up to 2 hours at 37uC, and then removed by
centrifugation, prior to the addition of virus. The mild periodate
oxidation was carried out with the addition of NaIO4 to the virus
for 10 minutes and followed by neutralization of the periodate
with glycerol [31]. For the Siglec blocking antibody experiments,
purified human IgG at 2 ug/mL was used to block non-specific
binding for 15 min prior to the addition of individual blocking
antibodies or controls. 20, 50, or 100 mg/mL of Siglec-1, -3, and
-9 blocking antibodies, or 100 mg/mL of mouse or sheep IgG
were used. The toxicity of each inhibitory compound was
assayed under conditions identical to the infection assay by
replacing virus with PBS. Cell viability was determined with Cell
Titer-Glo Luminescent Cell Viability Assay according to the
manufacturer’s recommendations (Promega). No measurable
toxicities were detected for sialyllactose at 100 mg/mL, neur-
aminidase at 1 U/mL, cyanovirin-N at 50 ng/mL, fetuin at
1 mg/mL, asialofetuin at 1 mg/mL, and recombinant Siglec-3,
-7 and -9 each at 100 mg/mL concentrations. The concentra-
tions that resulted in less than 20% reduction in cellular viability
were determined for periodate, EDTA, and glycerol to be 2 mM,
5 mM, and 20%, respectively.
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The R5-tropic Ba-L strain of HIV-1 virus (HIV-1BaL),
propagated using primary human macrophages, was purchased
from Advanced Biotechnologies Inc. (Columbia, MD). MDM
were resuspended at 3610
6/mL in culture media. Cells were
incubated at room temperature for 15 minutes with a test
compound or appropriate control. The concentrations of com-
pound or control used were: 50 mg/mL of sialyllactose or lactose,
100 ug/mL T20 (kindly provided by Dr. Tae-Wook Chun), or
PBS. Cells were exposed to HIV-1BaL, at concentrations of 500
(1X), 125 (1/4X), or 32.5 (1/8X) TCID50 (median tissue culture
infective dose) per 10
6 cells at 37uC for 1 hour, followed by
extensive washing. HIV-1BaL was shown to infect in a dose-
dependent manner based on concentrations used (Figures S6). The
MDM were then cultured in triplicate in 96-well plates (250 uL/
well) and incubated for 14 days. Culture supernatants were
collected (100 uL) and wells were replenished with fresh media on
days 1, 3, 6, 9, 12, and 14 post-infection (DPI). HIV-1 p24 activity
was assayed via ELISA according manufacturer recommendations
(Perkin Elmer). All statistical analyses were carried out using the
software Prism 5.05 (GraphPad Software, Inc.).
Supporting Information
Figure S1 Expression of Siglecs on transfected CHO cells. The
expression of Siglecs on transfected (grey shaded) and untrans-
fected (open histograms) CHO cells, stained with their respective
antibodies.
(DOC)
Figure S2 BIAcore binding between Siglec-3 and gp120. (A)
Binding of recombinant gp120 from 92US715 (0.65 mM),
92UG21-9 (0.49 mM), and PBj1.9 (0.2 mM) HIV-1 isolates onto
protein A-captured recombinant Siglec-3 Fc fusion protein. The
sensorgrams in each panel represent Siglec-3 captured in flow cells
2, 3, and 4 at various levels. Flow cell 1 has immobilized protein A
but no captured receptor (blank). (B) Binding of serial dilutions of
92US715 gp120 between 0.43–0.054 mMo r8 9SA-PAA between
0.062–20 mM onto immobilized Siglec-3 under high immobiliza-
tion density. All sensorgrams are shown in response units (vertical
axis) versus sample injection time (horizontal axis) in seconds. All
dissociation constants are listed in Table 1.
(DOC)
Figure S3 Effect of recombinant Siglec proteins and cyanovirin-
N (CVN) on R5- and X4-tropic HIV-1 and VSV. Single-round
infection of MDM with JRFL, SF33 and VSV pseudoviruses in the
presence of 100 mg/mL recombinant Siglec-3, Siglec-7, Siglec-9,
CVN (50 ng/mL), or PBS (100%).
(DOC)
Figure S4 The entry of various R5-(left side) and X4-(right side)
tropic HIV and VSV pseudoviruses into MDM with (grey) or
without (white) prior treatment with 0.5 U/mL neuraminidase for
1 hour. The observed enhancement in infections upon neuramin-
idase treatment of MDM is consistent with previously published
findings [22,23]. While the exact mechanism of neuraminidase-
mediated enhancement in infection remains unresolved, much of
the effect was attributed to the reduction in charge repulsion
between viral and host sialic acids [22,49]. However, our binding
results suggest that part of the neuraminidase effect is to unmask
cell surface Siglec receptors thus increasing their binding to viral
sialic acids. Indeed, cell surface-associated sialidase expression
could be induced during monocyte to macrophage differentiation
[50].
(DOC)
Figure S5 Effect of sialyllactose (SL) compared to lactose on
HIV-1BaL infection of MDM. Infection of MDM with HIV-1BaL
(125 TCID50) in the presence of 50 mg/mL sialyllactose (light grey
squares) or lactose (black circles), or 100 mg/mL T20 (dark grey
triangles). The results are shown as the level of HIV-1 p24 (ng/
mL) sampled over 14 days post infection (DPI).
(DOC)
Figure S6 Dose-dependent effect of sialyllactose (SL) on HIV-
1BaL infection of MDM. Infection of MDM with 500 TCID50
(black circles), 125 TCID50 (light grey squares), and 31.25 TCID50
(dark grey triangles) HIV-1BaL in the presence of 50 mg/ml
sialyllactose (A) or PBS (B) over 14 days. The results are shown as
the level of HIV-1 p24 (ng/mL) sampled over 14 days post
infection (DPI).
(DOC)
Figure S7 Amino acid sequences of R5 HIV-1 envelope gp120
from AD8, JRFL and DH125 strains. Predicted N-glycan sites are
highlighted in red. Regions corresponding to variable loops V1–
V5 are indicated. Significant variations in predicted N-glycan sites
exist among the sequences, particularly within the V1 and V4
loops.
(DOC)
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